{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:15:25Z","timestamp":1740147325006,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiologic entity characterized by headaches, altered mental status, seizures, visual loss, and a characteristic imaging pattern in brain magnetic resonance images.\u00a0The exact etiology and pathogenesis of this condition are not yet fully elucidated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 72-year-old White man presented with 2 weeks of low-grade fever and chills, night sweats, fatigue, dysphagia, and new-onset rapidly increasing cervical lymphadenopathy. He had\u00a0a history of chronic lymphocytic leukemia with transformation to diffuse large B-cell lymphoma for which he was started on dose-adjusted rituximab, etoposide, prednisone vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH). Shortly after treatment initiation, the patient developed severe airway obstruction due to cervical lymphadenopathy that required emergency intubation. A few days later, the cervical lymphadenopathy and the status of the airway improved, and sedation was consequently weaned off to plan for extubation. However, the patient did not recover consciousness and developed generalized\u00a0refractory seizures. Brain magnetic resonance imaging revealed edema in the cortical gray and subcortical white matter of the bilateral occipital and inferior temporal lobes, consistent with PRES.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Posterior reversible encephalopathy syndrome refers to a neurological disorder and imaging entity characterized by subcortical vasogenic edema in patients who develop acute neurological signs and symptoms of a usually reversible nature in different settings, including chemotherapy. Despite its name, PRES is not always fully reversible, and permanent sequelae can persist in some patients. Clinicians should be aware of the possible association between chemotherapy and PRES to ensure early recognition and timely treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-021-02780-y","type":"journal-article","created":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T23:03:02Z","timestamp":1618182182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Posterior reversible encephalopathy syndrome in a patient with Richter's syndrome on combination DA-R-EPOCH chemotherapy regimen: a case report"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5203-8156","authenticated-orcid":false,"given":"Goar","family":"Egoryan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Murguia-Fuentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Agab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagwa","family":"Abou-Ghanem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Adriana","family":"Yanez-Bello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bimatshu","family":"Pyakuryal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela Patricia","family":"Trelles-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Filipiuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adi","family":"Gidron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Rodriguez-Nava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"issue":"11","key":"2780_CR1","doi-asserted-by":"publisher","first-page":"E218","DOI":"10.1002\/ajh.23826","volume":"89","author":"T Tadmor","year":"2014","unstructured":"Tadmor T, Shvidel L, Bairey O, et al. Richter\u2019s transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding Rituximab to chemotherapy, from the Israeli CLLStudy Group: Richter\u2019s transformation to diffuse large B-cell lymphoma. Am J Hematol. 2014;89(11):E218\u201322. https:\/\/doi.org\/10.1002\/ajh.23826.","journal-title":"Am J Hematol."},{"issue":"15","key":"2780_CR2","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","volume":"115","author":"JA Sparano","year":"2010","unstructured":"Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115(15):3008\u201316. https:\/\/doi.org\/10.1182\/blood-2009-08-231613.","journal-title":"Blood"},{"issue":"8","key":"2780_CR3","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1007\/s00415-016-8377-8","volume":"264","author":"M Fischer","year":"2017","unstructured":"Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. J Neurol. 2017;264(8):1608\u201316. https:\/\/doi.org\/10.1007\/s00415-016-8377-8.","journal-title":"J Neurol."},{"issue":"9","key":"2780_CR4","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S1474-4422(15)00111-8","volume":"14","author":"JE Fugate","year":"2015","unstructured":"Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914\u201325. https:\/\/doi.org\/10.1016\/S1474-4422(15)00111-8.","journal-title":"Lancet Neurol."},{"key":"2780_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2007.46","author":"VH Lee","year":"2008","unstructured":"Lee VH, Wijdicks EFM, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008. https:\/\/doi.org\/10.1001\/archneurol.2007.46.","journal-title":"Arch Neurol."},{"issue":"5","key":"2780_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.4065\/mcp.2009.0590","volume":"85","author":"JE Fugate","year":"2010","unstructured":"Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85(5):427\u201332. https:\/\/doi.org\/10.4065\/mcp.2009.0590.","journal-title":"Mayo Clin Proc."},{"issue":"6","key":"2780_CR7","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ejpn.2015.07.005","volume":"19","author":"H Yamamoto","year":"2015","unstructured":"Yamamoto H, Natsume J, Kidokoro H, et al. Clinical and neuroimaging findings in children with posterior reversible encephalopathy syndrome. Eur J Paediatr Neurol. 2015;19(6):672\u20138. https:\/\/doi.org\/10.1016\/j.ejpn.2015.07.005.","journal-title":"Eur J Paediatr Neurol."},{"issue":"7","key":"2780_CR8","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3174\/ajnr.A0549","volume":"28","author":"WS Bartynski","year":"2007","unstructured":"Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. Am J Neuroradiol. 2007;28(7):1320\u20137. https:\/\/doi.org\/10.3174\/ajnr.A0549.","journal-title":"Am J Neuroradiol."},{"issue":"6","key":"2780_CR9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3174\/ajnr.A0929","volume":"29","author":"WS Bartynski","year":"2008","unstructured":"Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. Am J Neuroradiol. 2008;29(6):1043\u20139. https:\/\/doi.org\/10.3174\/ajnr.A0929.","journal-title":"Am J Neuroradiol."},{"issue":"1","key":"2780_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11912-008-0013-z","volume":"10","author":"C Vaughn","year":"2008","unstructured":"Vaughn C, Zhang L, Schiff D. Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep. 2008;10(1):86\u201391. https:\/\/doi.org\/10.1007\/s11912-008-0013-z.","journal-title":"Curr Oncol Rep."},{"issue":"1","key":"2780_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/ajh.20147","volume":"77","author":"CS Tam","year":"2004","unstructured":"Tam CS, Galanos J, Seymour JF, Pitman AG, Stark RJ, Prince HM. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol. 2004;77(1):72\u20136. https:\/\/doi.org\/10.1002\/ajh.20147.","journal-title":"Am J Hematol."},{"issue":"4","key":"2780_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.clml.2016.12.004","volume":"17","author":"AE Floeter","year":"2017","unstructured":"Floeter AE, Patel A, Tran M, et al. Posterior reversible encephalopathy syndrome associated with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) chemotherapy. Clin Lymphoma Myeloma Leuk. 2017;17(4):225\u201330. https:\/\/doi.org\/10.1016\/j.clml.2016.12.004.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"4","key":"2780_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/ajh.23402","volume":"88","author":"AE Hammerstrom","year":"2013","unstructured":"Hammerstrom AE, Howell J, Gulbis A, Rondon G, Champlin RE, Popat U. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol. 2013;88(4):301\u20135. https:\/\/doi.org\/10.1002\/ajh.23402.","journal-title":"Am J Hematol."},{"issue":"6","key":"2780_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00234-009-0504-0","volume":"51","author":"C Mueller-Mang","year":"2009","unstructured":"Mueller-Mang C, Mang T, Pirker A, Klein K, Prchla C, Prayer D. Posterior reversible encephalopathy syndrome: do predisposing risk factors make a difference in MRI appearance? Neuroradiology. 2009;51(6):373\u201383. https:\/\/doi.org\/10.1007\/s00234-009-0504-0.","journal-title":"Neuroradiology"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02780-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-021-02780-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02780-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T03:27:04Z","timestamp":1618630024000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-02780-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2780"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-02780-y","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2021,4,12]]},"assertion":[{"value":"25 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our institution does not require ethical approval for case reports.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient's next of kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"161"}}